Evidence map›Paper›PMID 28978014›Full record

ArticleOncotarget2017

Meta-analysis of association between rs1447295 polymorphism and prostate cancer susceptibility.

Juan Zhou, Yang Yu, Anyou Zhu, Fengchao Wang, Shuxia Kang, Yunfeng Pei, Chunping Cao, Chen Ding, Duping Wang, Li Sun and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Juan Zhou *Department of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.
Yang Yu *Department of Medical Oncology, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.
Anyou Zhu *Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Anhui, People's Republic of China.
Fengchao WangDepartment of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Anhui, People's Republic of China.
Shuxia KangDepartment of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Anhui, People's Republic of China.
Yunfeng PeiDepartment of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.
Chunping CaoDepartment of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.
Chen DingDepartment of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.
Duping WangDepartment of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.
Li SunDepartment of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.
Guoping NiuDepartment of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.
Southeast University · CNFirst Affiliated Hospital of Bengbu Medical College · CNXuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsA number of studies have found that the single nucleotide polymorphisms (SNPs) within the 8q24 region of genome were associated with the susceptibility of prostate cancer. Association between 8q24 SNP variant rs1447295 and higher risk of prostate cancer had been investigated, but those studies were incomplete and the conclusions were obscure.

methodsTo better elucidate the relationship between rs1447295 polymorphism and the susceptibility of prostate cancer, we performed a more comprehensive meta-analysis about the association between rs1447295 polymorphism and prostate cancer susceptibility by collecting relevant articles published up to November, 2016 and excluding many replicated cohort data existing in previous reports, which made the conclusion more reliant and objective.

resultsThe results showed that there was a significant prostate cancer risk associated with rs1447295 polymorphism not only in the total groups, but also in American, European and Asian descent subgroups. Meanwhile, a comprehensive analysis about the association between rs1447295 polymorphism and prostate cancer risk were conducted by using different clinical characteristic stratifications including Gleason score, tumor stage and PSA level. The result showed that rs1447295 polymorphism was correlated with different stages of prostate cancer.

conclusionsThere are strong association between rs1447295 polymorphism and prostate cancer susceptibility in different ethnic groups and different prostate cancer stage, suggesting that rs1447295 might serve as a reliable biomarker for prostate cancer diagnosis.

Indexed as

meta-analysisprostate cancerrs1447295susceptibility

Identifiers

PMID28978014
PMCPMC5620154
OpenAlexW2611107695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.